L. Bruni, G. Albero, M. Aldea, B. Serrano, S. Valencia et al., ICO Information Centre on HPV and Cancer (HPV Information Centre): Human Papillomavirus and, pp.12-18, 2014.

F. X. Bosch, A. Lorincz, N. Munoz, C. J. Meijer, and K. V. Shah, The causal relation between human papillomavirus and cervical cancer, J Clin Pathol, vol.55, issue.4, pp.244-65, 2002.

E. M. Burd, Human papillomavirus and cervical cancer, Clin Microbiol Rev, vol.16, issue.1, pp.1-17, 2003.

H. A. Katki, W. K. Kinney, B. Fetterman, T. Lorey, N. E. Poitras et al., Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice, Lancet Oncol, vol.12, issue.7, pp.663-72, 2011.

J. Cuzick, C. Clavel, K. U. Petry, C. J. Meijer, H. Hoyer et al., Overview of the European and north American studies on HPV testing in primary cervical cancer screening, Int J Cancer, vol.119, issue.5, pp.1095-101, 2006.

N. W. Bulkmans, J. Berkhof, L. Rozendaal, F. J. Van-kemenade, A. J. Boeke et al., Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial, Lancet, vol.370, issue.9601, pp.1764-72, 2007.

H. A. Cubie and K. Cuschieri, Understanding HPV tests and their appropriate applications, Cytopathology, vol.24, issue.5, pp.289-308, 2013.

C. J. Meijer, J. Berkhof, P. E. Castle, A. T. Hesselink, E. L. Franco et al., Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older, Int J Cancer, vol.124, issue.3, pp.516-536, 2009.

N. Santesso, R. A. Mustafa, H. J. Schunemann, M. Arbyn, P. D. Blumenthal et al., World Health Organization guidelines for treatment of cervical intraepithelial neoplasia 23 and screen-and-treat strategies to prevent cervical cancer, Int J Gynaecol Obstet, vol.132, issue.3, pp.252-260, 2016.

P. B. Moussavou, I. H. Koumakpayi, A. A. Nkili-meyong, I. Labouba, U. Bisvigou et al., Molecular analysis of human Papillomavirus detected among women positive for cervical lesions by visual inspection with acetic acid/Lugol's iodine (VIA/VILI) in Libreville, Gabon. Infect Agent Cancer, vol.11, issue.1, p.50, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02002416

A. M. De-roda-husman, J. M. Walboomers, A. J. Van-den-brule, C. J. Meijer, and P. J. Snijders, The use of general primers GP5 and GP6 elongated at their 3? ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR, J Gen virology, vol.76, pp.1057-62, 1995.

M. H. Schiffman, H. M. Bauer, R. N. Hoover, A. G. Glass, D. M. Cadell et al., Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia, J Natl Cancer Inst, vol.85, issue.12, pp.958-64, 1993.

C. A. Harwood, P. J. Spink, T. Surentheran, I. M. Leigh, E. M. De-villiers et al., Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts, J Clin Microbiol, vol.37, issue.11, pp.3545-55, 1999.

T. W. Remmerbach, U. G. Brinckmann, A. Hemprich, M. Chekol, K. Kuhndel et al., PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets, J Clinical Virol, vol.30, issue.4, pp.302-310, 2004.

B. J. Kocjan, P. J. Maver, L. Hosnjak, N. Zidar, K. Odar et al., Comparative evaluation of the Abbott RealTime high risk HPV test and INNO-LiPA HPV genotyping extra test for detecting and identifying human papillomaviruses in archival tissue specimens of head and neck cancers, Acta Dermatovenerol Alp Pannonica Adriat, vol.21, issue.4, pp.73-78, 2012.

M. Poljak, A. Ostrbenk, K. Seme, A. Sterbenc, and N. Jancar, Vrtacnik Bokal E. Threeyear longitudinal data on the clinical performance of the Abbott RealTime high risk HPV test in a cervical cancer screening setting, J Clin Virol, 2015.

S. Huang, N. Tang, W. B. Mak, B. Erickson, J. Salituro et al., Principles and analytical performance of Abbott RealTime high risk HPV test, J Clin Virol, vol.45, issue.1, pp.13-20, 2009.

S. J. Salipante, D. J. Sengupta, C. Rosenthal, G. Costa, J. Spangler et al., Rapid 16S rRNA nextgeneration sequencing of polymicrobial clinical samples for diagnosis of complex bacterial infections, PLoS One, vol.8, issue.5, p.65226, 2013.

J. Shendure and H. Ji, Next-generation DNA sequencing, Nat Biotechnol, vol.26, issue.10, pp.1135-1180, 2008.

M. P. Gailey, A. A. Stence, C. S. Jensen, and D. Ma, Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalinfixed, paraffin-embedded tissue, Cancer Cytopathol, vol.123, issue.1, pp.30-39, 2015.

J. E. Tota, A. V. Ramanakumar, M. Jiang, J. Dillner, S. D. Walter et al., Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination, Am J Epidemiol, vol.178, issue.4, pp.625-659, 2013.

J. E. Tota, A. V. Ramanakumar, L. L. Villa, H. Richardson, A. N. Burchell et al., Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens, Cancer Epidemiol Biomark Prev, vol.24, issue.1, pp.286-90, 2015.

A. M. Cornall, S. Phillips, E. Cummins, S. M. Garland, and S. N. Tabrizi, In vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: implications for postvaccine surveillance studies, J Virol Methods, vol.214, pp.10-14, 2015.

C. Arregui, A. Gariglio, P. Kanda, T. Doorbar, and J. , ONCOGENIC HUMAN PAPILLOMAVIRUSES: high-risk human Papillomaviruses: towards a better understanding of the mechanisms of viral transformation, latency and immune-escape, Open Virol J, vol.6, pp.160-162, 2012.

J. Cuzick, L. Ambroisine, L. Cadman, J. Austin, L. Ho et al., Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears, J Med Virol, vol.82, issue.7, pp.1186-91, 2010.

J. Cuzick, M. H. Mayrand, G. Ronco, P. Snijders, and J. Wardle, Chapter 10: new dimensions in cervical cancer screening, Vaccine, vol.24, 2006.

J. Choi, Y. Park, E. H. Lee, S. Kim, J. H. Kim et al., Detection and genotyping of human papillomavirus by five assays according to cytologic results, J Virol Methods, vol.187, issue.1, pp.79-84, 2013.

H. S. Chung, C. Hahm, and M. Lee, Comparison of the clinical performances of the AdvanSure HPV screening real-time PCR, the Abbott real-time high-risk HPV test, and the hybrid capture high-risk HPV DNA test for cervical cancer screening, J Virol Methods, vol.205, pp.57-60, 2014.

A. T. Hesselink, C. J. Meijer, M. Poljak, J. Berkhof, F. J. Van-kemenade et al., Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening, J Clin Microbiol, vol.51, issue.7, pp.2409-2419, 2013.

R. K. Gibb and M. G. Martens, The impact of liquid-based cytology in decreasing the incidence of cervical cancer, Rev Obstet Gynecol, vol.4, issue.1, pp.2-11, 2011.